Background: Musculoskeletal (MSK) manifestations are common in SLE. Many recent clinical trials were negative or had small benefits vs. placebo. SRI is a common primary endpoint but has not been independently validated. Ultrasound is an objective measure of synovitis validated in inflammatory arthritis.

Objectives: To compare the responsiveness of clinical outcome measures with ultrasound in MSK-SLE.

Methods: 20 SLE patients meeting SLICC 2012 criteria with inflammatory MSK symptoms were included. Clinical assessment (BILAG2004, SLEDAI-2K) was done over 30 days. Ultrasound was performed at 0, 2, and 4 weeks after 120 mg IM depomedrone. The study was assessed by hand grip and pinch grip strength, dexterity and ADL performance tests. Hand grip strength was measured by Jamar dynamometer, and pinch grip strength by pinch gauge, in both hands. Dexterity was measured by Purdue pegboard test. Disabilities of the Arm, Shoulder and Hand (DASH) questionnaire and Health Assessment Questionnaire (HAQ) were in used in order to determine the difficulties in ADLs.

Results: Hand grip strength, both lateral and jaws pinch grip strength, and dexterity, were significantly impaired (p<0.001) in both hands of SLE patients compared to healthy subjects (table 1). DASH questionnaire (19.75±20.93 vs 2.42±2.9, p<0.001) and Health Assessment Questionnaire score (HAQ) (0.41±0.52 vs 0.03 ±0.52, p<0.001) were also significantly different between SLE patients and healthy controls.

Conclusions: These findings demonstrate that SLE patients have lower grip, pinch strength and dexterity and more difficulties in ADL performance. These findings underline the need to develop specific hand therapy programs for SLE patients.

REFERENCES:
AB0593 PREDICTORS OF FATIGUE AND SEVERE FATIGUE IN A LARGE MULTICENTER INTERNATIONAL COHORT OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: THE FATLUP STUDY
L. Arnaud1, P. E. Gavand2, Z. Amoura3, G. Blaison4, R. Voill4, A. Schwartzzöng, N. Magy Bertrand1, F. Maurier4, J.-L. Pennaforte5, V. Poindron2, P. Kieffer1, B. Bonnote1, H. Lorenz2, C. Fiehn13, J. Sibilia1, T. Martin2, on behalf of LBBR Medicine, CHU Reims, Reims; 1Internal Medicine, CH Metz, Metz; 2Internal Medicine, CHU Reims, Reims; 3Internal Medicine, CH Mulhouse, Mulhouse; 4Internal Medicine, CHU Dijon, Dijon, France; 5University of Heidelberg, Heidelberg; 6Unit for Rheumatology and Clinical Immunology, Medical Center Baden-Baden, Baden Baden, Germany

Background: Fatigue is an important issue in systemic lupus and has a major impact on quality of life of the patients. Data are controversial about the factors associated with this complex symptom.

Objectives: To identify the factors associated with fatigue and severe fatigue in patients with systemic lupus erythematosus (SLE) in a large cohort using a multivariate model to precise the importance of each parameter in this multidimensional method.

Methods: We used the LBBR data base, a German French data base of SLE patients. All patients fulfilled the 1997 ACR criteria for SLE. The Fatigue Scale for Motor and Cognitive Functions (FSMC) was used to assess fatigue and severe fatigue. The depression and anxiety were measured with Hospital Anxiety and Depression Scale (HADS). Tests were performed at sampling.

Results: A total of 570 patients were included (89.1% female). The median age was 42 years (QR25–75: 34–52). The median value of the SELENA-SLEDAI was 2 (QR25–75: 0–4) and 136 patients had a SELENA-SLEDAI score >6. Fatigue was reported by 386 patients (67.7%) including severe fatigue by 209 (36.7%). In univariate analysis among the individual components of the SLEDAI arthritis (p=0.003) and oral ulcers (p<0.002) were associated with severe fatigue. In multivariate analysis fatigue was strongly associated with anxiety (OR: 4.49 [95%CI: 2.60–7.77], p<0.0001) and depression (OR: 4.72 [95%CI: 1.39–16.05], p<0.01). It was also associated with age at sampling (OR: 1.01 [95%CI: 1.00–1.03], p=0.03) per 1 year increase), SLEDAI (OR: 1.05 [95%CI: 1.00–1.12], p=0.043) per 1 SLEDAI point increase) and glucocorticoids treatment (OR: 1.54 [95%CI: 1.00–2.38], p=0.04). It was not associated with physical activity. Severe fatigue was strongly associated with depression (OR:6.87 [95%CI: 3.12–15.11], p<0.0001) and anxiety (OR: 3.80 [95%CI: 2.46–5.87], p<0.0001) but not with SLEDAI or physical activity.

Conclusions: Fatigue is a common symptom in SLE patients and is strongly associated with anxiety and depression. While remission remains an important therapeutic target, these manifestations should also be taken care of with psychological counselling and pharmacological intervention, when needed.

REFERENCE:

Disclosure of Interest: None declared
DOI: 10.1136/annrheumdis-2018-eular.2188

AB0594 PREVALENCE OF FRACTURE IN WOMEN WITH SLE, THEIR CONNEXION WITH THE COURSE OF THE DISEASE AND THE NATURE OF PHARMACOTHERAPY
S. Shevchuk, L. Demyshchyk, E. Shevchuk. National Pirogov Memorial Medical University, Vinnytsia, Ukraine

Background: Patients with rheumatic diseases are known to have the risk of osteoporosis and fragility fractures. Women with SLE are associated with the reduction in bone mass density (BMD) in systemic lupus erythematosus (SLE) patients. The role of the disease severity and the activity of the inflammatory process in the reduction BMD and the incidence of fractures in SLE patients is discriminative.

Objectives: The aim of the study was to determine the frequency of osteoporosis and fragility fractures in the Ukrainian SLE patients and to establish their connexion with the course of the disease.

Methods: The main study group involved 91 women with a diagnosis of SLE according to the American College of Rheumatology criteria. The disease activity was determined using the SLE Disease Activity Index (SLEDAI), and organ damage was measured using the Systemic Lupus International Collaborating Clinics American College of Rheumatology (SLICC/ACR) Damage Index. In all patients the cumulative dose of glucocorticoids was calculated. Serum CRP and IL-6 levels were determined by immunoassay. BMD at the lumbar spine (L1–L4) and femoral neck were measured using dual-energy X-ray absorptiometry. For pre-menopausal SLE patients BMD by Z-score <-2.0 SD was defined as «below expected range for age». For post-menopausal women osteoporosis was defined by T-scores – 2.5 SD, and osteopenia – between –1.0 and –2.5 SD. To determine fractures female SLE patients were examined with x-ray.

Results: In pre-menopausal SLE patients the abnormal BMD of the lumbar spine was found in 9.8%, at the level of the femoral neck it was in 11.1%, in postmenopausal SLE patients – 18.4 and 13.6%, respectively. In the control group there was any premenopausal woman with low bone mass at both sites, whereas among postmenopausal individuals, these were 12.5 and 6.2%, respectively.

Osteoporotic fractures were detected in 13 (14.2%) SLE patients, of which 30.7% had hip fractures and 69.3% had vertebral fractures. The reduction of bone strengths and fractures were associated with a high damage index. In particular, in persons with fractures it equalled to 4.85±0.65, and in persons without fractures – 3.09±0.22, points. A similar tendency was detected by the disease activity SLEDAI. Glucocorticoid use also had a negative effect on the bone strength in patients with SLE. Thus, in women with fractures, the cumulative dose of glucocorticoids defined 60±86.63 g, and was by 37.1% higher than in patients without fractures.

Conclusions: In patients with SLE the prevalence of low BMD and fragility fractures is high. Progressive loss of the BMD and the occurrence of osteoporotic fractures are closely associated with the severity of organ damage and glucocorticoid use.

Disclosure of Interest: None declared

AB0595 ANTIPHOSPHOLIPID SYNDROME (HUGHES SYNDROME) IS A DISEASE WITH PROTEAN FACES: MULTIDISCIPLINARY APPROACHES ON SERBIAN COHORT OF APS PATIENTS
L. Stojanovich, A. Djikovic, N. Stanisavljevic, G. Bogdanovic, M. Zdravkovic. Internal medicine department, University Hospital Center Bezanjica Kosa, Belgrade, Serbia

Background: Antiphospholipid syndrome (APS) is a systemic autoimmune disease characterised by thrombophilic state and circulating antiphospholipid antibodies (aPL) including anti beta2-GPI complex.

Objectives: Since it than became one of the most systemic conditions. In the last three and half decades, a variety of clinical manifestations involving almost all organs and tissues (cardiac, pulmonary, neurological, renal, cutaneous, hematologic, gastrointestinal, oculair, skeletal and endocrinologic), have been described associated with antiphospholipid antibodies (aPL).

Methods: Our study comprises a total of 608 patients: 420 primary APS (PAPS) patients and 188 SLE patients with secondary APS (SAPS). aPL analysis included detection of aCL, aβ2GPI, and LA.

Results: Thrombosis was diagnosed in 46.5% patients, with higher prevalence in PAPS compared to SAPS patients: 51.2% and 38.3%, respectively, p=0.045. Pseudoimmune endocarditis was observed in 12.8% secondary APS patients and 3.1% in primary APS patients (p=0.004). 30% of the patients with high levels of aCL IgG antibodies had valve thickening and dysfunction, as compared to 4.1% without valve abnormalities (p=0.002). Presence of β2GPI IgG was significantly related to stroke, and overall β2GPI (IgG and IgM) positivity was significantly related to TIA in SAPS patients. Valvular manifestations were significantly related to TIA in both groups of patients and were independent risk factors for TIA in PAPS (OR 3.790 (1.597–8.998 p=0.003: table 2). In PAPS, epilepsy correlated with β2GPI-IgM, migraine with aCL-IgM, thrombocytopenia with aCL-IgM, aCL-IgG, aβ2GPI-IgG and LA. Livedo reticularis was more prominent in PAPS patients with high levels of aCL-IgG. Skin ulcerations were more prevalent in aCL-IgM positive SAPS patients and epilepsy more frequently had high levels of aβ2GPI-IgG in SAPS.

Conclusions: In this cross-section analysis of a large cohort of APS patients we analysed that APS patients can be presented with a wide variety of thrombotic